BR0306798A - Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes. - Google Patents
Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.Info
- Publication number
- BR0306798A BR0306798A BR0306798-0A BR0306798A BR0306798A BR 0306798 A BR0306798 A BR 0306798A BR 0306798 A BR0306798 A BR 0306798A BR 0306798 A BR0306798 A BR 0306798A
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes mellitus
- type
- parts kit
- treatment
- melagatran
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"USO DE MELAGATRAN OU DE UM DERIVADO FARMACEUTICAMENTE ACEITáVEL DESTE, MéTODOS DE TRATAMENTO DE DIABETES MELLITUS TIPO I, DE TRANSPLANTE DE CéLULAS, DE ENXERTAMENTO DE ILHOTAS DE LANGERHANS, PARA MELHORAR A INDEPENDêNCIA DE INSULINA EM PACIENTES COM DIABETES MELLITUS TIPO I, E DE TRATAMENTO DE REAçãO INFLAMATóRIA MEDIADA PELO SANGUE INSTANTâNEA, FORMULAçãO FARMACêUTICA PARA USO NO TRATAMENTO DE DIABETES MELLITUS TIPO I, KIT DE PARTES, E, MéTODO DE FABRICAçãO DE UM KIT DE PARTES". De acordo com a invenção é fornecido o uso de melagatran, ou um derivado farmaceuticamente aceitável deste, para a fabricação de um medicamento para o tratamento de diabetes Tipo I.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200198A SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | New use |
| PCT/SE2003/000087 WO2003061682A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0306798A true BR0306798A (pt) | 2004-12-07 |
Family
ID=20286751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0306798-0A BR0306798A (pt) | 2002-01-23 | 2003-01-21 | Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7045502B2 (pt) |
| EP (1) | EP1469874A1 (pt) |
| JP (1) | JP2005516035A (pt) |
| KR (1) | KR20040075096A (pt) |
| CN (1) | CN100430089C (pt) |
| BR (1) | BR0306798A (pt) |
| CA (1) | CA2472241A1 (pt) |
| IL (1) | IL162853A0 (pt) |
| MX (1) | MXPA04007192A (pt) |
| NO (1) | NO20043483L (pt) |
| NZ (1) | NZ533749A (pt) |
| SE (1) | SE0200198D0 (pt) |
| WO (1) | WO2003061682A1 (pt) |
| ZA (1) | ZA200405342B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| KR102113960B1 (ko) | 2010-03-30 | 2020-05-21 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
| EP2968297B1 (en) | 2013-03-15 | 2018-09-26 | Verseon Corporation | Multisubstituted aromatic compounds as serine protease inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| WO2016044662A1 (en) | 2014-09-17 | 2016-03-24 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| WO2016138532A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| WO2020014669A1 (en) | 2018-07-13 | 2020-01-16 | Verseon Corporation | Thrombin inhibitors, formulations, and uses thereof |
| EP4384193A2 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| AR005245A1 (es) | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
| SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SE523817C2 (sv) | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
-
2002
- 2002-01-23 SE SE0200198A patent/SE0200198D0/xx unknown
-
2003
- 2003-01-21 NZ NZ533749A patent/NZ533749A/en unknown
- 2003-01-21 CA CA002472241A patent/CA2472241A1/en not_active Abandoned
- 2003-01-21 US US10/502,069 patent/US7045502B2/en not_active Expired - Fee Related
- 2003-01-21 IL IL16285303A patent/IL162853A0/xx unknown
- 2003-01-21 BR BR0306798-0A patent/BR0306798A/pt not_active IP Right Cessation
- 2003-01-21 KR KR10-2004-7011228A patent/KR20040075096A/ko not_active Application Discontinuation
- 2003-01-21 CN CNB038026740A patent/CN100430089C/zh not_active Expired - Fee Related
- 2003-01-21 MX MXPA04007192A patent/MXPA04007192A/es unknown
- 2003-01-21 JP JP2003561625A patent/JP2005516035A/ja active Pending
- 2003-01-21 WO PCT/SE2003/000087 patent/WO2003061682A1/en active Application Filing
- 2003-01-21 EP EP03701203A patent/EP1469874A1/en not_active Withdrawn
-
2004
- 2004-07-05 ZA ZA2004/05342A patent/ZA200405342B/en unknown
- 2004-08-20 NO NO20043483A patent/NO20043483L/no not_active Application Discontinuation
-
2006
- 2006-02-24 US US11/362,890 patent/US20060148720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040075096A (ko) | 2004-08-26 |
| US20060148720A1 (en) | 2006-07-06 |
| WO2003061682A1 (en) | 2003-07-31 |
| US20050090424A1 (en) | 2005-04-28 |
| MXPA04007192A (es) | 2004-10-29 |
| NO20043483L (no) | 2004-08-20 |
| CA2472241A1 (en) | 2003-07-31 |
| CN100430089C (zh) | 2008-11-05 |
| IL162853A0 (en) | 2005-11-20 |
| JP2005516035A (ja) | 2005-06-02 |
| EP1469874A1 (en) | 2004-10-27 |
| SE0200198D0 (sv) | 2002-01-23 |
| CN1729010A (zh) | 2006-02-01 |
| NZ533749A (en) | 2006-02-24 |
| US7045502B2 (en) | 2006-05-16 |
| ZA200405342B (en) | 2005-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0211649D0 (en) | Organic compounds | |
| NO20050569L (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| MY142551A (en) | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | |
| CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| EA200501420A1 (ru) | Устройство доставки для лекарственной и клеточной терапии | |
| WO2004112711A3 (en) | Oral extended-release composition | |
| HRP20130406T1 (hr) | Medikamenti s aktivnošä†u prema receptoru hm74a | |
| EP1803721A4 (en) | INNOVATIVE GLUCITOL DERIVATIVE, PRECURSOR OF THE MEDICINAL PRODUCT AND SALT THEREOF, AND A THERAPEUTIC AGENT FOR DIABETES CONTAINING THE SAME | |
| HUP0401998A2 (hu) | PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető | |
| NO20061859L (no) | OROS Push Stick for kontrollert tilforsel av aktive midler | |
| CY1114863T1 (el) | Στερεο παρασκευασμα | |
| NO20052914L (no) | Terapeutiske forbindelser | |
| MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
| ATE493981T1 (de) | Einmal tägliche dosierformen von trospium | |
| PE20011074A1 (es) | Uso de pramipexol en el tratamiento de trastornos de adiccion | |
| WO2005016867A3 (en) | Anthranilic acid derivatives and their use as activators of the hm74a receptor | |
| BR0306798A (pt) | Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes. | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
| NO20072089L (no) | Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| IS8373A (is) | Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |